Sanofi is a large pharma headquartered in France. Over the past three years, Sanofi has been involved in 38 licensing and acquisition transactions, with a primary focus on Other (9 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
12
Active Trials
50
Top Modality
Other
Focus Area
Oncology
Licensing, acquisition, and partnership transactions involving Sanofi in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| Dynavax adjuvant and vaccine portfolio | Dynavax Technologies | Vaccines | Unknown | acquisition | Jun 15, 2026 |
| Blueprint Medicines portfolio | Blueprint Medicines | Small Molecules | Unknown | acquisition | May 15, 2026 |
| mRNA influenza vaccine program | MIT Anderson Lab | mRNA | Phase 1 | collaboration | May 14, 2026 |
| NanoDisc platform | Evoq Therapeutics | Other | Preclinical | license | May 2, 2026 |
| duvakitug | Teva | Antibodies | Phase 2 | collaboration | Apr 17, 2026 |
| AXPAXLI | Ocular Therapeutix | Other | Phase 3 | acquisition | Apr 1, 2026 |
| AXPAXLI | Ocular Therapeutix | Other | Phase 3 | acquisition | Mar 31, 2026 |
| rovadicitinib | Sino Biopharmaceutical | Small Molecules | Phase 2 | license | Mar 4, 2026 |
| Deep B-cell depletion platform (DR-0201 and additional candidates) | Dren Bio | Other | Unknown | collaboration | Dec 15, 2025 |
| Anti-SIRPα-501 | Verve Therapeutics | Small Molecules | Phase 2 | collaboration | Nov 19, 2025 |
Showing 10 of 15 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where Sanofi is most active based on deal history and clinical trial data.
Key indicators of Sanofi's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Sanofi has 50 active clinical trials across 6 development phases.
9
Unknown
6
Phase 4
2
Not Applicable
4
Phase 1
10
Phase 2
19
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Sanofi is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 38 deals over the past three years, Sanofi ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sanofi include Oncology (21 deals and trials), Mega Deals (8 deals and trials), Autoimmune (7 deals and trials), and Metabolic (7 deals and trials). In terms of modality, Sanofi has shown particular interest in other, small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sanofi and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Sanofi's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals